Benign Prostatic Hyperplasia in Taiwan
Benign Prostatic Hyperplasia in Taiwan
Primary Objective:

 -  To assess the sexual function of Benign Prostatic Hyperplasia patients

 Secondary Objective:

 -  To evaluate the association between Lower Urinary Tract Symptoms severity and sexual
 disorders

 -  To compare the sexual function, urinary symptoms and Quality of Life of Benign Prostatic
 Hyperplasia patients on XATRAL 10mg OD among the different regions

 -  To correlate the Male Sexual Health Questionnaire(MSHQ) and 5-item version of the
 International Index of Erectile Function (IIEF-5)

 -  To assess the onset of action of XATRAL 10mg OD

 -  To assess the peak urinary flow rate

 -  To assess the safety and the tolerability of XATRAL 10mg OD
Inclusion criteria

 -  Male suffering from moderate to severe lower urinary tract symptoms (LUTS), suggestive
 of symptomatic Benign Prostatic Hyperplasia (BPH)

 -  Sexually active

 -  Sexual attempts at least once per month

 Exclusion criteria

 -  Known history of hepatic or severe renal insufficiency

 -  unstable angina pectoris

 -  concomitant threatening-life condition

 -  Previous transurethral resection of the prostate (TURP)

 -  Had a minimally invasive procedure within 6 months prior to inclusion

 -  Planned prostate surgery or minimally invasive procedure during the whole study period

 -  Active urinary tract infection or acute prostatitis

 -  Neuropathic bladder

 -  Diagnosed prostate cancer

 -  Patients having received 5-reductase inhibitors or Lower Urinary Tract Symptoms (LUTS)
 related phytotherapy or anti-muscarinics drug for OAB or 1-blockers within 1 month
 prior to inclusion

 -  Patients receiving any treatment for erectile dysfunction within 1 month prior to
 inclusion

 -  History of postural hypotension or syncope

 -  Known hypersensitivity to alfuzosin

 -  Patients illiterate or unable to understand or to complete the questionnaires

 -  Patients having participated in any clinical study in the past month

 -  Prostate Specific Antigen (PSA)> age specific Prostate Specific Antigen value, without
 using prostate biopsy to rule out prostate cancer

 The above information is not intended to contain all considerations relevant to a patient's
 potential participation in a clinical trial.